This is NOT a solicitation announcement. This is a sources sought synopsis only for market research. The purpose of this sources sought is to gain knowledge of potential qualified sources and their size classification relative to NAICS 325412 (size standard of 1250 employees). Responses to this sources sought will be used by the Government to make appropriate acquisition decisions. After review of the responses to this sources sought, a solicitation announcement may be published. Responses to this sources sought synopsis are not considered adequate responses for a solicitation announcement. The Department of Veterans Affairs (VA), VISN 22 Network Contracting Office, is seeking sources that can provide Hazardous Compounded Chemotherapy Drugs for the VA Long Beach Healthcare System, Long Beach, CA 90822. The period of performance will approximately start April 1, 2019 to September 30, 2020 with the Government having the option to exercise two (2) one-year renewal periods through September 30, 2022. **Upon completion of compounding, products will be transported VIA FedEx to VA Long Beach Healthcare System prior to Chemotherapy Infusion date. Must be able to provide next day delivery and be able to provide the entire list of hazardous compounded chemotherapy drugs on as it pertains to the terms and conditions stated within statement of work (SOW). (See SOW) Ado-Trastuzumab Azacitidine Bortezomib Cabazitaxel Carboplatin Carboplatin Etoposide Carboplatin Fluorouracil Carboplatin Gemcitabine Carboplatin Pemetrexed Carfilizomib Cisplatin Cisplatin Docetaxel Cisplatin Etoposide Cisplatin Ifosfamide Cyclophosphamide Dacarbazine Docetaxel Docetaxel Carboplatin Doxorubacin Vincristine Cyclophosphamide Doxorubicin Doxorubicin Bleomycin Dacarbazine Doxorubicin Bleomycin Vinblastine Dacarbazine Doxorubicin Cyclophosphamide Doxorubicin Vincristine Cyclophosphamide Etoposide Etoposide Carboplatin Ifosfamide mesna Etoposide Cisplatin Etoposide Vincristine Doxorubicin Fluorouracil Gemcitabine Cisplatin Gemcitabine Docetaxel Gemcitabine PB Paclitaxel Irinotecan Irinotecan Fluorouracil Liposomal Irinotecan Methotrexate Methotrexate Hydrocortisone Mitomycin Mitomycin Opth Oxaliplatin Oxaliplatin Fluorouracil Paclitaxel Paclitaxel Carboplatin PB Paclitaxel Gemcitabine Pemetrexed Pemetrexed Carboplatin Pertuzumab Romidepsin Topotecan Ado-trastuzumab emtansine Carfilzomib Cisplatin Gemcitabine Cyclophosphamide Cyclophosphamide Vincristine Cytarabine Erlbulin Mesylate Etoposide Carboplatin Ifosfamide Etoposide Carboplatin Ifosfamide Mensa Floxuridine Leucovorin Fludarabine Cyclophosphamide Gemcitabine Gemcitabine Carboplatin Idarubicin Irinotecan Carboplatin P. B. Paclitaxel P. B. Paclitaxel Gemcitabine Pentuzumab Carboplatin Docetaxel Vincristine Vinorelbine Vinorelbine Cisplatin *Estimated Shipping for delivery orders must be included within the purchase. The information identified above is intended to be descriptive, not restrictive and to indicate the quality of the supplies/services that will be satisfactory. It is the responsibility of the interested source to demonstrate to the government that the interested parties can provide the supplies/services that fulfill the required specifications. If you are interested, and are capable of providing the sought supplies, please provide the requested information as well as the information indicated below. Response to this notice should include company name, address, point of contact, size of business pursuant to the following questions: (1) Please indicate the size status and representations of your business, such as but not limited to: Service Disabled Veteran Owned Small Business (SDVOSB), Veteran Owned Small Business (VOSB), Hubzone, Woman Owned Small Business (WOSB), Large Business, etc. (2) Is your company considered small under the NAICS code identified under this source sought announcement? (3) Are you the manufacturer or distributor of the items being referenced above (or equivalent product/solution)? What is the manufacturing country of origin of these items? (4) If you re a small business and you are an authorized distributor/reseller for the items identified above (or equivalent product/solution), do you alter; assemble; modify; the items requested in any way? If you do, state how and what is altered; assembled; modified? (5) Does your company have an FSS contract with GSA or the NAC or are you a contract holder with NASA SEWP or any other federal contract? If so, please provide the contract type and number. (6) If you are an FSS GSA/NAC or NASA SEWP contract holder or other federal contract holder, are the referenced items/solutions available on your schedule/contract? (7) Please provide general pricing for your products/solutions for market research purposes. (8) Please submit your capabilities in regards to the salient characteristics being provided and any information pertaining to equal to items to establish capabilities for planning purposes? *** Submissions addressing Section (8) should show clear, compelling and convincing*** evidence that all equal to items" meet all required salient characteristics. Responses to this notice shall be submitted via email to [email protected]. Telephone responses shall not be accepted. Responses must be received no later than January 16, 2019 at 12NOON, PST. If a solicitation is issued it shall be announced at a later date, and all interested parties must respond to that solicitation announcement separately from the responses to this request for information. Responses to this notice are not a request to be added to a prospective bidders list or to receive a copy of the solicitation.

Bid Protests Not Available